AnaptysBio Inc's stock soared 5.23% during Monday's intraday trading session, following a positive analyst update from Truist Securities.
The surge came after Truist Securities raised its price target on AnaptysBio to $50 from $36, while maintaining a Hold rating on the stock. This significant upward revision in the price target likely provided a catalyst for investor optimism, driving the share price higher.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.